No Data
Jinhe Biotechnology Includes Sheep, Lambs in Registration of Animal Diarrhea Medication
Jinhe Biotech: Report for the third quarter of 2024
jinhe biotechnology (002688.SZ): net income of 0.114 billion yuan in the first three quarters, a year-on-year increase of 10.38%.
Gelonghui October 27th | Jinhe Biotechnology (002688.SZ) announced that in the first three quarters of 2024, it achieved revenue of 1.657 billion yuan, a year-on-year increase of 5.57%; net income attributable to shareholders of the listed company was 0.114 billion yuan, a year-on-year increase of 10.38%, with basic earnings per share of 0.1461 yuan.
Jinhe Biotechnology (002688.SZ) released its performance for the first three quarters, with a net income of 0.114 billion yuan, a year-on-year increase of 10.38%.
jinhe biotechnology (002688.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
jinhe biotechnology (002688.SZ): Repurchase completed, cumulative expenditure of 50.0988 million yuan to repurchase 15.2215 million shares.
GeLongHui October 11th | Jinhe Biotechnology (002688.SZ) announced that as of October 10, 2024, the company has cumulatively repurchased 15.2215 million shares, accounting for 1.97% of the company's total share capital. The highest fill price was 5.16 yuan/share, and the lowest fill price was 2.92 yuan/share, with a total transaction amount of 50.0988 million yuan (excluding transaction costs). This buyback plan has been completed.
Jinhe Biotechnology's (SZSE:002688) Earnings Have Declined Over Five Years, Contributing to Shareholders 25% Loss
Some Jinhe Biotechnology CO., LTD. (SZSE:002688) Shareholders Look For Exit As Shares Take 27% Pounding
